Résultats
Roivant présente des résultats positifs de la phase 2 pour le médicament contre l'hypertension pulmonaire mosliciguat
Le médicament inhalé de Roivant, mosliciguat, a montré une réduction de 56,3 % de la résistance vasculaire pulmonaire dans son étude de phase 2, ouvrant la voie à une étude de phase 3 pouvant impliquer jusqu'à 375 patients.
Funding Circle lifts 2026 outlook as shares fall
Funding Circle raised full-year 2026 revenue and profit targets after first-half results, but its shares fell 8.7% to $210.
Novartis Loses Around 24 Billion Francs as Shares Tumble Over Research Setbacks
Novartis shares fell more than 10% after a second significant research disappointment in days, erasing around 24 billion francs in market value and setting a historic single-day loss.
Libstar profit dips on integration costs and weak exports in H1 2026
South African food producer Libstar Holdings reported a decline in normalized EBITDA and a sharp fall in operating profit for the half-year, weighed down by integration costs and a weaker rand impacting export sales.
Uniphar H1 2026 profit rises as growth plan stays on track
Uniphar's adjusted EPS rose 11.2% to EUR 0.109 in the first half of 2026, with EBITDA up 6.2% and management reaffirming its EUR 200 million EBITDA target by 2028.
Rubis raises 2026 EBITDA guidance on 18% half-year profit growth
Rubis lifted full-year 2026 EBITDA guidance to €775-825 million after first-half EBITDA rose 18% to €434 million and net income increased 17% to €191 million.
Novartis del-desiran fails phase 3 trial, top asset from $12B Avidity buyout
The centerpiece drug from Novartis's $12 billion Avidity Biosciences acquisition missed its primary endpoint in a phase 3 trial for myotonic dystrophy type 1, sending shares down 12.5%.
Rubis Lifts Full-Year Outlook on Strong H1 2026 Results
Rubis raised its 2026 EBITDA guidance to EUR 775-825 million after reporting a 18% jump in first-half EBITDA to EUR 434 million, driven by robust performance across Africa, the Caribbean and Europe.
Dunelm FY26 profit steady as free cash flow rises 21.5%
UK homewares retailer Dunelm reported flat pre-tax profit of £211m and steady 76.8p EPS, while free cash flow rose 21.5% to £154.8m and total dividends reached 70.5p.
Dunelm Reports Flat Profits as Sales Grow 3.1% in FY2026
UK homewares retailer posts £1.825bn revenue with gross margin expanding to 52.5%, though profit before tax held flat at £211m amid inflationary cost pressures.
Shiprocket Q1 FY27 revenue accelerates to 34% on margin gains
Shiprocket's first-quarter fiscal 2027 revenue rose 34% to INR 592 crore, while adjusted EBITDA rose nearly ninefold and core EBITDA margin reached 12.8%.
Sandoz dévoile ses objectifs de croissance pour les biosimilaires jusqu'en 2035
Le fabricant de médicaments génériques a revu à la hausse ses prévisions de revenus et de marges à long terme, en s'engageant à faire des biosimilaires la principale composante de ses ventes d'ici 2035 dans le cadre de son programme Bio100.
Les revenus d'Emyria FY 2026 ont triplés à 4,05 millions de dollars australiens alors que le réseau de cliniques s'est développé
Emyria a enregistré des recettes au cours de l'exercice 2026 d'un montant de 4,05 M$ AUD, en hausse de 191 % par rapport à 1,39 M$ AUD, après avoir passé de une clinique à cinq et avoir soigné 138 patients.
Emyria reports 208% revenue rise in FY 2026 as clinic network expands
Emyria Ltd posted FY 2026 revenue of just over AUD 4 million, up 207.7% from the prior year, while adding four clinics and scaling treatment capacity for PTSD and depression.
SCREEN Holdings posts weaker Q1 FY2027 but lifts full-year outlook
Japanese semiconductor equipment maker reported a 10% drop in sales for the quarter ended June 30, 2026, while raising its FY2027 revenue and profit forecasts.
SCREEN Holdings raises full-year sales outlook to record JPY 743 billion after soft Q1
The semiconductor equipment maker lifted its full-year sales target to JPY 743 billion and raised its 2026 wafer fab equipment growth forecast to over 20%.
Partners Group reports H1 results; Layton steps down as CEO
Management income rises 6% to CHF 905m as AuM reaches USD 186bn; Co-CEOs Cagnati and Jenkner appointed effective January 2027.
IQE shares up 4% as AI and data‑centre demand lifts H1 revenue 43%
British semiconductor materials maker IQE reported first‑half revenue of £64.6 million, a 43% year‑on‑year rise, driven by AI and data‑centre orders, and saw its shares climb 4.1% in early London trade.
Quanex beats Q3 2026 forecasts, shares surge 21%
Adjusted EPS of $0.79 and revenue of $501.8 million topped estimates, sending the stock up 20.6% in after‑hours trading.
LU-VE Group enregistre une hausse des ventes de 10 %, un backlog record au 1er semestre 2026
Le fabricant italien de systèmes de refroidissement a enregistré une croissance de 10,5% des ventes de produits, un fort regain des commandes, correspondant à une augmentation de 48 %, et a ajusté ses prévisions à moyen terme après avoir remporté un contrat de 100 millions d'euros auprès d'un hyperscaler.
SigmaRoc H1 2026 EBITDA climbs 11% ahead of €110m Dolomitas deal
The aggregates group posted £523.1m revenue and a 25.1% EBITDA margin, while confirming a €110m acquisition of Lithuania's Dolomitas to be completed in Q4 2026.
SigmaRoc H1 2026 profit growth lifts shares 12.6%
SigmaRoc posted 2.6% revenue growth, an 11.3% rise in EBITDA and a 12.2% EPS increase in the first half of 2026, sending its stock up 12.6% to $144.5.
LU-VE posts record Q2 2026 revenue as order backlog jumps 48%
The Italian thermal management firm reported $171.7 million revenue for Q2, a 10.3% YoY increase, and a backlog exceeding €333 million, up 48% year‑over‑year.
Team Internet publie un bénéfice d'exploitation au 1er semestre 2026, alors que les marges se sont améliorées
La société cotée à Londres a enregistré un bénéfice d'exploitation positif pour le premier semestre de 2026, avec une marge brute qui a augmenté à 34,1 %, malgré une diminution de 16 % des revenus nets.